Treatment of Epilepsy in Pregnancy

Nulman, I.; Laslo, D.; Koren, G.
April 1999
Drugs;Apr1999, Vol. 57 Issue 4, p535
Academic Journal
Pregnant women with epilepsy constitute 0.5% of all pregnancies. Proper seizure control is the primary goal in treating women with epilepsy. The commonly used anticonvulsants are established human teratogens. Factors such as epilepsy, anticonvulsant-induced teratogenicity, patient’s genetic predisposition and the severity of convulsive disorder may attribute to adverse pregnancy outcome for the children of women with epilepsy. Anticonvulsant interaction with folic acid and phytomenadione (vitamin K) metabolism may lead to an increased risk for neural tube defect and early neonatal bleeding. Psychological, hormonal and pharmacokinetic changes in pregnancy may escalate seizure activity. Preconceptional counselling should include patient education to ensure a clear understanding of risks of uncontrolled seizures and possible teratogenicity of anticonvulsants. Genetic counselling should be performed if both parents have epilepsy or the disease is inherited. Seizure control should be achieved at least 6 months prior to conception and, if clinically possible, by the lowest effective dose of a single anticonvulsant according to the type of epilepsy. The new anticonvulsants are not recommended in pregnancy and require further research to prove their safety in humans. Folic acid 5 mg/day should be administered 3 months before conception and during the first trimester to prevent folic acid deficiency-induced malformations. Antenatal management should include assessment of patients for anticonvulsant-associated birth defects through detailed ultrasound examination and levels of maternal serum α-fetoproteins. Therapeutic drug monitoring should be performed monthly, or as clinically indicated. If phenobarbital, carbamazepine or phenytoin is administered, maternal phytomenadione supplementation should begin 4 weeks before the expected date of delivery. In order to prevent convulsions during labour, proper seizure control should be achieved during the third trimester. Benzodiazepines or phenytoin are found to be effective for seizure cessation during labour and delivery. Phytomenadione should be administered immediately after birth to the newborn. The neonate should be assessed carefully for epilepsy and anticonvulsant-associated dysmorphology. Advising the patient on postpartum management regarding contraception and breast-feeding will help maximise the best possible outcome for the newborn and mother. With proper preconceptional, antenatal and postpartum management up to 95% of these pregnancies have been reported to have favourable outcomes.


Related Articles

  • Epilepsy and pregnancy. O'Brien, M.D.; Gilmour-White, S. // BMJ: British Medical Journal (International Edition);8/21/93, Vol. 307 Issue 6902, p492 

    Examines epilepsy in pregnant women. Suggestion of a withdrawal of antiepileptic drug treatment before a planned pregnancy; Reasons for the increased risk of epilepsy during delivery; Measurement of progesterone concentrations to ensure that ovulation is being suppressed.

  • Epilepsy and pregnancy. Mamoli, D.; Ratti, S.; Battino, D. // Neurological Sciences;Feb2003, Vol. 23 Issue 6, p267 

    Editorial. Discusses the teratogenicity of antiepileptic drugs used by epileptic mothers. Incidence of birth defects; Relative risks associated with different antiepileptic drugs; Safety of antiepileptic drugs in the human fetus.

  • Management of women with epilepsy: from preconception to post-partum. Laganà, Antonio; Triolo, Onofrio; D'Amico, Valeria; Cartella, Sandy; Sofo, Vincenza; Salmeri, Francesca; Vrtačnik Bokal, Eda; Spina, Edoardo; Laganà, Antonio Simone; Cartella, Sandy Maria; Salmeri, Francesca Maria; Vrtačnik Bokal, Eda // Archives of Gynecology & Obstetrics;Mar2016, Vol. 293 Issue 3, p493 

    Purpose: The physiological changes during pregnancy can significantly alter antiepileptic drug (AED)'s absorption, distribution, metabolism and elimination, thus influencing their plasma concentration. Considering that the risks of using old and new AEDs during pregnancy are still...

  • The Importance of Increased Clearance of Lamotrigine during Pregnancy. Ben-Menachem, Elinor // Epilepsy Currents;Mar/Apr2005, Vol. 5 Issue 2, p59 

    Discusses research being done on the effects of lamotrigine (LTG) monotherapy on pregnant women with epilepsy. Reference to a study by G. J. De Haan and colleagues published in the 2004 issue of the "Neurology" journal; Findings that an increase in LTG clearance is responsible for the change in...

  • Pregnancy and epilepsy: what should we tell our patients? Tomson, Torbjörn; Battino, Dina // Journal of Neurology;Jun2009, Vol. 256 Issue 6, p856 

    Women with epilepsy that plan to become pregnant can in general look forward to uneventful pregnancies and to giving birth to normal children. However, there are certain risks associated with epilepsy and antiepileptic drug (AED) treatment, and it is likely that these risks can be reduced with...

  • Pharmacokinetics and therapeutic drug monitoring of newer antiepileptic drugs during pregnancy and the puerperium. Tomson, Torbjörn; Battino, Dina; Tomson, Torbjörn // Clinical Pharmacokinetics;2007, Vol. 46 Issue 3, p209 

    The treatment of epilepsy in pregnancy is particularly challenging in that the fetal and maternal risks associated with maternal seizures need to be balanced against the potential teratogenic effects of antiepileptic drugs (AEDs). Pregnancy is known to affect the pharmacokinetics of...

  • Identifying Major Congenital Malformations in the UK General Practice Research Database (GPRD). Charlton, Rachel A.; Weil, John G.; Cunnington, Marianne C.; de Vries, Corinne S. // Drug Safety;2010, Vol. 33 Issue 9, p741 

    Background: Postmarketing teratogen surveillance is essential and requires a data source that can reliably capture a wide range of congenital malformations. The UK General Practice Research Database (GPRD) may have the potential to be used for this kind of surveillance. Objective: To assess the...

  • Management of Epilepsy during Pregnancy. Battino, Dina; Tomson, Torbjörn // Drugs;2007, Vol. 67 Issue 18, p2727 

    Managing epilepsy during pregnancy is to balance the maternal and fetal risks associated with uncontrolled seizures against the potential teratogenic effects of antiepileptic drugs (AEDs). A rational approach requires knowledge of such risks as well as an understanding of the effects of...

  • Fetal sodium vaiproate exposure causes Baller-Gerold syndrome phenotype: both phenotypes in the same family. Özdemir, Özmert M. A.; Kılıç, İlknur; Özsarı, Tamer; Kılıç, B. Alper; Faivre, Laurence; Aral, Bernard; Gürses, Dolunay; Semerci, C. Nur // Turkish Journal of Pediatrics;Nov/Dec2009, Vol. 51 Issue 6, p631 

    Baller-Gerold syndrome (BGS) is characterized by craniosynostosis and pre-axial upper-limb malformations, and it has an autosomal recessive inheritance. Valproate syndrome occurs after exposure to vaiproic acid in utero, and is characterized by trigonocephaly. Both syndromes can also present...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics